Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: J Clin Immunol. 2012 Oct 9;33(2):397–406. doi: 10.1007/s10875-012-9801-1

Fig. 1 — Longitudinal analysis of liver and immune function in PSC + IBD patients during OV treatment. Serum (a) gamma-glutamyl transpeptidase (GGT) and (b) alanine aminotransferase levels (IU/L) over 12 months of OV (n=8). (c) Peripheral count (K/uL) of WBC, neutrophils, and lymphocytes over 12 months of OV (n=6). (d) Longitudinal changes in cytokine production patterns from Th1 (TNFα), Th2 (IL-4, IL-13), and Treg (TGF-β) subtype cells before and 3 months post OV administration in a separate cohort of children with PSC+IBD (n=6) initially reported on in the original Cox et al study [2]

Fig. 1 — Longitudinal analysis of liver and immune function in PSC + IBD patients during OV treatment. Serum (a) gamma-glutamyl transpeptidase (GGT) and (b) alanine aminotransferase levels (IU/L) over 12 months of OV (n=8). (c) Peripheral count (K/uL) of WBC, neutrophils, and lymphocytes over 12 months of OV (n=6). (d) Longitudinal changes in cytokine production patterns from Th1 (TNFα), Th2 (IL-4, IL-13), and Treg (TGF-β) subtype cells before and 3 months post OV administration in a separate cohort of children with PSC+IBD (n=6) initially reported on in the original Cox et al study [2]